The attached document is a 78 page PDF file obtained from USTR under the Freedom of Information Act (copy here), regarding communications between Gilead and USTR, over Malaysia’s decision to grant a compulsory license on patents for HCV treatments.
This includes several emails and documents, including but not limited to the following:
2017 January 17-20
World Economic Forum Annual Meeting – Davos, Switzerland. There is a meeting held between Malaysian Minister of Economic Affairs and Gregg Alton, Executive Vice President, Corporate and Medical Affairs of Gilead Sciences (referenced in June 23, 2017 email from Barry Featherman).
2017 June 18-19
Karl Ehlers of USTR writes to Daniel Lee and Barbara Weisel of USTR and Barry Featherman and Gregg Alton of Gilead, regarding facilitating a meeting between Featherman, Briana Baron (Gilead) and the Malaysian Embassy, “per our discussion with Gregg Alton.”
2017 June 22
A meeting is held at the Embassy of Malaysia between Barry Featherman, Senior Director, International Government Affairs, Briana Barron, Senior Counsel, Intellectual Property, and Lorie Ann Morgan, VP for Intellectual Property of Gilead and Hairil Yahri Yaacob, Minister Counselor, Ministry of Economic Affairs and Mohd Firdaus Mohd Ali, Second Secretary, Ministry of Economic Affairs of Malaysia.
Gilead discussed the decision by the Malaysian government to reject Gilead’s claim of data exclusivity.
2017 June 23
Karl Ehlers (USTR) emails Barry Featherman (Gilead) to ask how June 22nd meeting between Gilead and Malaysian Embassy went.
Barry Featherman (Gilead) sends report to Karl Ehler (USTR) of the June 22 meeting at the Malaysian embassy. Among other things, Gilead told USTR that: “even in the absence of data exclusivity, our data should still be protected under TRIPS.” Gilead reported the Malaysian officials from the Ministry of Economics encouraged Gilead to meet directly with the officials at the Ministry of Health. The Malaysian officials from the Ministry of Economics said they would also ask their headquarters to weigh in with the Ministry of Health and they asked Gilead to send them more information about their Minister’s meeting with Gregg Alton at Davos in January 2017. Meeting participants included Barry Featherman (Gilead), Briana Barron (Gilead), Lori Ann Morgan (Gilead via teleconference), Hairil Yahri Yaacob (Malaysian Minister Counselor of Economics), and Mohd Firdaus Mohd Aldi (Malaysian Second Secretary of Economics).
2017 August 22
Gregg H. Alton (Gilead) letter to HE Datuk Seri KV Subramaniam (Malaysian Minster of Health), re: “Request for meeting to discuss HIV and hepatitis C proposal from Gilead Sciences, Inc.”
I hope this finds you well since we last met at the February 2015 Wilton Park meeting in Singapore, “HIV co-infections with viral hepatitis: implications for screening and treatment in Asia.” I am writing to request a meeting with you to discuss how we can work together to address HIV/AIDS and hepatitis C in Malaysia. We are committed to making our innovative HIV/AIDS and hepatitis C treatments available to patients in Malaysia and would like to propose adding Malaysia to the list of countries eligible to receive licensed generic versions of our HIV and hepatitis C medicines. If your schedule permits, I will be in Australia and can travel to Kuala Lumpur to discuss this proposal with you on Friday September 1 or anytime that is convenient for you.
Barry Featherman (Gilead) emails Karl Ehlers (USTR), Barbara Weisel (USTR), and Daniel Lee (USTR) asking if they have time to speak today.
2017 August 24
Gregg Alton (Gilead) letter to HE Dato’ Sri Mustapa Mohamed (Malaysian Minister of International Trade and Industry), re: “Request for meeting to discuss HIV and hepatitis C partnership with Gilead Sciences, Inc.”
I hope this finds you well since we last met at the World Economic Forum in January. As I mentioned then, Gilead is committed to making our innovative HIV/AIDS and hepatitis C treatments available to patients in Malaysia. I am pleased to share that we are expanding the reach of our HIV and hepatitis C and HIV voluntary licensing program to include Malaysia, as well as Belarus, Thailand and Ukraine. We would appreciate the opportunity to meet with you to discuss this program expansion. Stanley Li, our General Manager responsible for Malaysia, and Aaron Brinkworth, Senior Director of Access Operations and Emerging Markets, will be in Kuala Lumpur the week of September 4 if your schedule permits.
We decided to increase the scope of our voluntary licensing program following a number of discussions with government officials, non-governmental organizations (NGOs) and community groups regarding the issues Malaysia and these three countries have experienced in expanding access to HIV and hepatitis C therapies. We hope that the inclusion of Malaysia in both our direct HIV and hepatitis C licenses, as well as in our indirect license for our HIV medicines through the Medicines Patent Pool (MPP), will help you and your government reach HIV and hepatitis C patients in need of life-saving treatment…
2017 August 28
Karl Ehlers writes to Hairil Yahri Yaacob and Mohd Firdaus Mohd Ali (Malaysia), introducing them to USTR’s Abigail Bacak, to schedule a meeting between Malaysia trade minister Mustapa Mohamed and USTR Robert Lighthizer.
2017 August 30
Mohd Firdaus Mohd Ali writes to Karl Ehlers and Abigail Bacak of USTR, with a letter requesting a meeting with Malaysia trade minister Mustapa Mohamed and USTR Robert Lighthizer.
2017 September 1
Abigail Bacak of USTR writes Mohd Firdaus Mohd Ali of Malaysia and Karl Ehlers of USTR with Barbara Weisel of USTR and Hairil Yahri Yaacob of Malaysia copied, to say the meeting between Malaysia trade minister Mustapa Mohamed and USTR Robert Lighthizer will be 45 minutes on September 11.
2017 September 5
Karl Ehler (USTR) email to Barry Featherman (Gilead) with Barbara Weisel (USTR) and Daniel Lee (USTR) copied.
Barry,
We were wondering if you have heard back from MYS regarding the meeting requests with Minister of Health or Minister of Trade?
Best, Karl
2017 September 9
Mohd Firdaus Mohd Ali (Malaysia) writes to Karl Ehlers of USTR, attaching a tentative agenda for a meeting between E. Mustapa Mohamed, Minister of International Trade and Industry, Malaysia and Ambassador Robert Lighthizer, U.S. Trade Representative. The tentative agenda was for an exchange of views on 7 topics plus “other areas of specific concern.”
2017 September 11
Meeting between E. Mustapa Mohamed, Minister of International Trade and Industry, Malaysia and Ambassador Robert Lighthizer, U.S. Trade Representative.
2017 September 12
Malaysian Prime Minister Najib has meeting with President Trump
2017 September 14
Barry Featherman of Gilead writes to Karl Ehlers of USTR.
“Dear Karl: I hope all is well. I send you warm greetings from Singapore. We’re very concerned by a report in Malaysia’s The Star (the first article below) that Malaysia’s cabinet approved issuing compulsory licenses to import generic versions of sofosbuvir to treat patients in public health facilities. Whilst we were aware of this, the concerning part is that Malaysia’s Health Ministry said that it is preparing a statement on the development. Additional coverage from Malay Mail Online is included, along with a statement from the Malaysian AIDS Council that notes the government decision was made August 4. I am curious if you have heard any news about the government’s forthcoming statement on this development. Many thanks! Barry”
Karl Ehlers (USTR) replies to above email from Barry Featherman (Gilead) with Daniel Lee (USTR) and Barbara Weisel (USTR) copied.
Barry,
We hadn’t heard about this. As your team gathers information and confirms the current status, please keep us posted.
Best,
Karl
2017 September 18
The Malaysia government issued an Exercise of Government’s Rights Under Section 84 Patents Act 1983 [Act 291) to authorize Pharmaniaga Logistics Sdn Bhd, Malaysia to exploit the patented invention for Sofosbuvir.
2017 September 19
Email from Karl Ehlers (USTR) to Barry Featherman (Gilead) with subject line “Any updates on your requested meeting with Ministry of Health?”
I was just speaking with the Malaysia Embassy, and they were wondering too. Best, Karl
2017 September 21
Call between Barry Featherman (Gilead) and Daniel Lee (USTR), Karl Ehlers (USTR), and Shannon Nestor (USTR), Marc Knox (Gilead) copied.
2017 September 26
Meeting between Karl Ehlers (USTR), Barry Featherman (Gilead), Gregg Alton (Gilead), Daniel Lee (USTR, by phone from Ottawa) as well as Shannon Nestor (USTR), Christina Olson (USTR), Marc Knox (Gilead) copied.
2017 October 2
Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs of Gilead Sciences, meets with then Malaysian Minister of Health Subramaniam Sathasivam.
2017 October 2
Gregg H. Alton (Gilead) letter sending additional information to then-Malaysian Minister of Health Subramaniam Sathasivam regarding the addition of Malaysia to the Gilead voluntary license of HIV and hepatitis C drugs.
Gregg H. Alton (Gilead) sent a letter to Prime Minister of Malaysia the Honourable Dato’ Sri Mohd Najib bin Tun Abdul Razak regarding “Gilead Sciences voluntary licensing of HIV and hepatitis C medicines in Malaysia.”
I write regarding the recent addition of Malaysia to the list of countries eligible to receive licensed generic versions of Gilead Sciences’ HIV and hepatitis C medicines. I would like to take this opportunity to share the full benefits of our voluntary licensing program, and explain the specific ways in which our voluntary licensing program can help expedite and expand access to generic versions of our medicines.
…
In summary, we believe that it is unnecessary and counterproductive for the Government of Malaysia to exercise its rights pursuant to Section 84(1)(a) of the Patents Act 1983 [Act 291], as our direct licensing agreements could help Malaysia reach more patients sooner. We have expressed these sentiments during our conversations in the United States…
2017 October 4
Meeting between PhRMA and USTR, regarding “SE pharmaceutical issues.” USTR says it “ would like to start with Vietnam and Malaysia.” PhRMA said its group would include Chris Kuzmuk (PhRMA), Chris Moore (PhRMA), Ruben Duran (PhRMA), Amey Sutkowski (PhRMA, likely), Megan Falken (GSK), Doug Goudie (Pfizer), Laurel Vogelsang (Merck). The USTR people in the email thread are Daniel Lee, Christine Brown, Karl Ehlers, Marta Prado, Christina Olsen. Email chain organizing meeting spans Sept 10-Oct 3, begins with request from Daniel Lee of USTR to Chris Kuzmuk of PhRMA to discuss SE Asia pharmaceutical issues.
2017 October 5
Following Oct 4th meeting, Chris Kuzmuk (PhRMA) emailed Daniel Lee (USTR and Karl Ehlers (USTR) with Amey Sutkowski (PhRMA) and Ruben Duran (PhRMA) CC’d for “a good contact at the Malaysian Embassy, as they’ve been a bit unresponsive to us at this point!”
Karl Ehlers (USTR) promptly responds with card file and direct email of Hairil Yahri Yaacob and card file of Mohd Firdaus Mohd Ali of Malaysian Embassy. Mentions that they’ll likely hear back from Firdaus but if not to let USTR know and they will contact Malaysians.
2017 October 7
Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs of Gilead Sciences, sent a letter to Prime Minister of Malaysia the Honourable Dato’ Sri Mohd Najib bin Tun Abdul Razak regarding the October 2 meeting with Minister of Health Subramaniam Sathasivam. Gregg H. Alton notes that the purpose of this meeting was to explain the Minister of Health “the benefits of a voluntary license over the use of Section 84”. The October 7 letter states:
“In light of the availability of a voluntary license for not only our hepatitis C medicines, but also our HIV and hepatitis B medicines, we would be disappointed if your government decides to exercise its rights pursuant to Section 84(1)(a) of the Patents Act 1983 [Act 291] on sofosbuvir. We believe the use of Section 84 is unnecessary and may become counterproductive in the development of a sustainable ecosystem of voluntary licensing, which could ultimately help Malaysia reach more patients sooner.”
Gregg Alton (Gilead) letter to HE Datuk Seri KV Sathasivam Subramaniam (Malaysian Minister of Health) following up on their meeting.
…We hope you will consider the benefits of a voluntary licensing approach as you endeavor to treat hepatitis C patients in Malaysia. In the meantime, we intend to appeal the Section 84(1)(a) decision and have requested a hearing before the Minister of Domestic Trade as soon as possible. Gilead is concerned with the procedure by which we were informed of the decision, our opportunity for appeal, and the reasons for the decision.
At our meeting we presented several new items for your consideration. We are at your disposal at any time should you have questions regarding our voluntary licensing program. I think that we would both agree that the 7- day deadline to respond to your compulsory license decision should not serve to unduly truncate your ability to fully review our proposal. Although we made an official request for an extension via the Malaysian Embassy in Washington, D.C., I hope that you will look favorably upon our request given the fruitful discussions we have started.
As we discussed, a comprehensive voluntary licensing model approach would better serve your public and private patients, show Malaysia’s willingness to use public private partnerships to meet the needs of its citizens, and serve as a strong multinational innovator model that other companies will wish to emulate.
I look forward to further discussions as you consider our voluntary licensing proposal and next steps. As a first step to addressing your questions, I am attaching two lists per your request:
1) A list of our current Indian voluntary licensees; and
2) The contact information for our local representatives.
2017 October 25
Following October 5th email chain, Chris Kuzmuk (PhRMA) emails Karl Ehlers (USTR) stating that they have not heard back from Hairil Yahri Yaacob (Malaysia) after several emails, and requesting his phone number. Karl responds promptly providing Mohd Firdaus Mohd Ali’s (Malaysia) cell phone number and offering that Christine Brown (USTR) will get them them Hairil’s contact information if not.
2017 October 31
Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs of Gilead Sciences sends a letter to Datuk Dr Noor Hisham bin Abdullah, Director General of Health at the Malaysia Ministry of Health. In this letter, Gregg H. Alton acknowledges that he spoke with Dr Noor Hisham bin Abdullah and then Malaysian Minister of Health Subramaniam Sathasivam on October 2. In this letter Gregg H. Alton states that:
“Given the availability of a voluntary license for not only our hepatitis C medicines, but also our HIV and hepatitis B medicines, we would be disappointed if the Malaysian government decides to exercise its right pursuant to Section 84(1)(a) of the Patents Act 1983 [Act 291] on sofosbuvir. We believe the use of Section 84 is in violation of local and international laws and treaties, unnecessary and may become counterproductive in the development of a sustainable ecosystem of voluntary licensing, which could ultimately help Malaysia reach more patients sooner.”
2017 November 3
Letter (on letterhead) from Gregg Alton to G. Payne Griffin (USTR) regarding “our recent issues in Malaysia.”
Dear Mr. Griffin:
Thank you for taking the time to meet last week to discuss our recent issues in Malaysia.
As we discussed, Malaysia’s recent issuance of a compulsory license on our hepatitis C medicine, sofosbuvir, represents a potential violation of TRIPS and other international patent protection regimes.
The Malaysian government’s action directly harms Gilead’s business in Malaysia. We believe the Malaysian government’s recent actions – both the unnecessary and inappropriate use of government license and data exclusivity rejections – warrant U.S. government engagement.
Left unchecked, these decisions set a precedent and send a clear message to other countries, particularly in the region, that disrespect for American intellectual property will be tolerated by the U.S. government. We understand others in the biotech and pharmaceutical industry are closely following our issue due to their concern about the potential impact on their interests in Malaysia and other global markets.
Since we met, we have been informed by the Malaysian government that they have rejected our appeals on the rejection of data exclusivity for both our HIV medicine, Genvoya, and our hepatitis C medicine, Harvoni. No explanation was provided in the appeal rejection letter, which is attached.
We would appreciate USTR’s support on these matters and hope Ambassador Lighthizer will communicate the U.S. government’s concerns to the Government of Malaysia, preferably by sending a letter expressing the U.S. government’s disappointment in these developments. We understand there could also be an opportunity to discuss our issues with the Government of Malaysia on the margins of the upcoming APEC Summit in Danang.
Thank you again for your time and consideration.
Best Regards,
Gregg Alton
CC:
Ambassador Robert Lighthizer, U.S. Trade Representative
Elizabeth Kendall, Acting Assistant U.S. Trade Representative for Innovation and Intellectual Property
Karl Ehlers, Acting Assistant U.S. Trade Representative for Southeast Asia and the Pacific
Daniel Lee, Deputy Assistant U.S. Trade Representative for Innovation and Intellectual Property
Attachments:
Notification of data exclusivity appeal rejection
Summary of compulsory license issue
Summary of data exclusivity rejections
Correspondence to the Prime Minister
Correspondence to the Minister of Health
Correspondence to the Minister of International Trade
Correspondence to the Director General of the Ministry of Health
2017 November 4
Letter from Gregg Alton (Gilead) to Payne Griffin (USTR) with Elizabeth Kendall (USTR), Karl Ehlers (USTR), and Daniel Lee (USTR) copied titled, “Thank you letter to G. Payne Griffin USTR 11.3.17” stating, “Please find a letter regarding our issues in Malaysia including updates regarding our data exclusivity rejections, attached.” (Attachment is dated November 3rd, noted above)
2017 November 7
Barry Featherman (Gilead) sends email to Karl Ehlers (USTR), Daniel Lee (USTR), Elizabeth Kendall (USTR), titled “Fwd: Malaysian agreement to import generic SOF”. Gilead is objecting to the agreement between DNDi and Pharco regarding the supply of ravidasvir and sofosbuvir to Pharmaniaga, on two grounds.
Please see below for recent press articles referring to Pharmaniaga’s agreement with Pharco and DNDi on sofosbuvir. The stated date of the agreement is July 26, 2017 for ten years. This seems problematic on two fronts: 1) this agreement pre‐dates the Cabinet’s decision to authorize the public use taking and 2) the public use taking is for a three‐year duration yet the agreement is for ten years.
Best, Barry
Malaysian drugmaker Pharmaniaga announced it entered into a collaboration with Pharco Pharmaceuticals and DNDi to promote access to affordable ravidasvir and sofosbuvir in Malaysia. The announcement notes that generic sofosbuvir importation is allowable under Section 84 of Malaysia’s Patents Act 1983 and TRIPS. The agreement is a ten‐year deal, effective July 26, 2017. Coverage follows from The Sun Daily, The Star, The Edge Markets and M2 Pharma.
2017 December 9
Email from Barry Featherman (Gilead) to Karl Ehlers (USTR) and Daniel Lee (USTR).
Hi Karl and Daniel: Just a note that I am once again enroute to Kuala Lumpur. The Minister of Domestic Trade has sent us a note offering to meet with us on Monday. I’ll let you know how the meeting goes. Best, Barry
2017 December 9
Email from Karl Ehlers (USTR) to Barry Featherman (Gilead), cc to Daniel Lee (USTR)
Barry
That is great news, thanks for letting us know. Are you also going to see Nat Turner of the Embassy, and Catherine Spillman of FCS? Assuming you will, but just checking as they have their meeting coming up with the Prime Minister’s office and I am sure a conversation w you would be helpful to them beforehand. K.
2017 December 10 to 13
WTO 11th Ministerial meeting in Buenos Aires, Argentina.
2017 December 10
Email from Courtney Gillespie (Gilead) to Karl Ehlers (USTR), Daniel Lee (USTR) with Gregg Alton (Gilead), Kacy Hutchison (Gilead), Chuck Clapton (Gilead), Barry Featherman (Gilead), Michael Pascual (Gilead), Joseph Damond (BIO), subject line “[EXTERNAL] Thank you and follow-up, Gilead Sciences.”
Karl and Daniel,
Thank you for taking the time to meet with us last week. We appreciated the opportunity
to discuss the compulsory license of sofosbuvir in Malaysia with you. Please find an
updated summary and timeline of engagement with the Malaysian government attached
for your background. Please let us know if you would like additional information in
advance of this week’s MC11 meeting.
We would welcome the opportunity to provide a readout of our December 11 meeting
with the Ministry of Domestic Trade. Perhaps we can plan to reconnect on Friday,
December 15 or the week of December 18.
Best,
Courtney
2017 December 11
Gilead meeting with Malaysia Ministry of Domestic Trade, in Kuala Lumpur. Michael Pascual (Gilead), Barry Featherman (Gilead) and others.
2017 December 12
Email from Joseph Damond of BIO to Elizabeth Kendall, of USTR. Subject, “Following up on Israel”
While I have you Elizabeth (know you are busy) two other quick things:
–Saw Daniel Lee on Thursday with Gilead about Malaysian CL — getting to be a big deal to industry, given that Gilead has tried to do everything right on pricing.
–Letting the TRIPS moratorium on non-violation nullification and impairment cases expire would be a big deal for this industry — in the sense that we’d greatly favor the expiration.
Hope all is well!
2017 December 14.
Subject line: “Thank you and follow-up, Gilead Sciences”
Michael Pascual (Gilead) wrote to Daniel Lee (USTR).
Hi Daniel, I am in DC tomorrow and was in the meeting with the Minister of Domestic Trade this past Monday. I’d be happy to meet with you tomorrow to give you a readout. Just let me know.
Best, Mike Michael Pascual | Director, Government Affairs, Asia | Gilead Sciences Hong Kong
2017 December 15
Meeting at main USTR building to brief USTR on the Dec 11th meeting between Gilead and the Malaysian Minister of Domestic Trade.
One of the emails concerning the meeting had the subject line “Re: Thank you and follow‐up, Gilead Sciences,” and was send by Daniel Lee (USTR), to Monica He (BIO) and Joseph Damond (BIO), with Cc: to Michael Pascual (Gilead); Courtney Gillespie; Gregg Alton (Gilead); Kacy Hutchison (Gilead); Chuck Clapton (Gilead); Barry Featherman (Gilead); Steward B. Young (USTR) and Karl Ehlers (USTR).
2017 December 15
Email from Michael Pascual of Gilead (Director of Government Affairs, Asia) to Karl Ehlers (USTR) and Nathaniel Turner (USTR), cc to Daniel Lee (USTR), Barry Featherman (Gilead), Courtney Gillespie (Gilead) and Dean Thompson. Subject is “Request to meet with PMO advisors.”
Karl,
It was a pleasure meeting you today and thanks for your offer to help facilitate a meeting with the Prime Minister’s office. Would you and Na be able to assist with requesting a meeting anytime January 4-8, 2018? Please let me know if you need anything from me to start that process. I also defer to you which advisor in the PM’s office would be most useful to engage — Saiful, Efendi, or someone else.
2017 December 16
Email from Karl Ehlers (USTR) to Nathaniel Turner (State), Michael Pascual (Gilead), cc to Courtney Gillespie (Gilead), Dean Thompson (State), Daniel Lee (USTR), Barry Featherman (Gilead).
Mike,
It was great to chat – in particular, thanks for letting us know that you have already responded to the Minister of Domestic Trade and made a proposal per his request. Keep us posted on what you hear from his office.
Re: a contact at the PMO’s office when you are next in KL, as we discussed, we think it would be a good idea to socialize your proposal if you can get a meeting. We’ll confer with Dean and Nat and Catherine; they will be able to advise on the best way to get a request in.
2018 January 17
Email from Gregg Alton of Gilead to Payne Griffin of USTR, requesting a meeting with Ambassador Lighthizer at the World Economic Forum in Davos. The request was for Robin Washington, the CFO of Gilead, and Alton.
Mr. Griffin,
I write to request a meeting with Ambassador Lightinzer at the upcoming World Economic Forum in Davos, Switzerland. Robin Washington, our Chief Financial Officer and Executive Vice President, and I will be in Davos and would appreciate the opportunity to discuss Malaysia’s recent issuance of a compulsory license on our hepatitis C medicine, sofosbuvir.
As we discussed last October, Malaysia’s compulsory license represents a potential violation of TRIPS and other international patent protection regimes. The Malaysian government’s action directly harmed Gilead’s business in Malaysia. We believe the Malaysian government’s recent actions warrant U.S. government engagement.
Left unchecked, these decisions set a precedent and send a clear message to other countries, particularly in the region, that disrespect for American intellectual property will be tolerated by the U.S. government. Since the Malaysian compulsory license was announced, both the Chilean parliament and Colombian Ministry of Health have made similar announcements regarding hepatitis C medicines.
We understand others in the biotech and pharmaceutical industry are closely following our issue due to their concern about the potential impact on their interests in Malaysia and other global markets.
Emails arranging call between USTR and PhRMA regarding “recent developments in Malaysia (email subject line: Malaysia), requested by USTR. Email chain includes Daniel Lee (USTR), Karl Ehlers (USTR), Chris Moore (PhRMA), and Chris Kuzmuk (PhRMA). Daniel Lee notes in his request for a call that he and Karl “are planning to make a stop in Malaysia as part of a broader trip to the region next week.”
2018 January 18
Call between Daniel Lee (USTR) and Chris Moore (PhRMA), possibly Karl Ehlers (USTR) others, regarding updates on “recent developments” in Malaysia.
2018 January 19
Email no body available from Daniel Lee (USTR) to Michael Pascual (Gilead), subject line “Accepted: [EXTERNAL] Re: Thank you and follow-up, Gilead Sciences”
2018 February 8
Email from Daniel Lee (USTR) to Chris Moore (PhRMA) and Chris Kuzmuk (PhRMA), asking if PhRMA is “already planning to do a multi-hour briefing for the Special 301 interagency sub-committee.”
2018 February 22-23
Emails arranging meeting on “ASEAN issues” specifically citing Indonesia and Malaysia, between USTR and PhRMA, requested by Chris Kuzmuk of PhRMA. Karl Ehlers (USTR), Daniel Lee (USTR), Christine Brown (USTR), and Chris Kuzmuk (PhRMA) on the chain.
Daniel Lee (USTR) notes he will miss the meeting, but will be at “the PhRMA Special 301 briefing” on March 7th.
2018 February 28
Meeting between PhRMA and USTR regarding ASEAN, touching bases on Indonesia and Malaysia.
2018 April 5
Call between PhRMA and USTR regard ASEAN. Email chain discussing call began with request from Chris Kuzmuk (PhRMA) to Marta Prado (USTR), Karl Ehlers (USTR), and Daniel Lee (USTR) to discuss ASEAN markets, including Thai TIFA meetings, Vietnam, Philippines, Indonesia, and “our quickly becoming favorite Malaysia.”
Among those included in the email chain setting the call.
USTR
Karl Ehlers (USTR)
Marta Prado (USTR)
Ronald Baumgarten (USTR)
Bartholomew Thanhauser (USTR)
Daniel Lee (USTR)
PhRMA
Chris Kuzmuk (PhRMA),
Catherine Hinckley (Eli Lilly)
Matthew Lloyd Watkins (Pfizer)